Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2029

ヒトマイクロバイオームの世界市場予測(~2029):製品別、用途別、疾患別、研究技術別

◆タイトル:Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2029
◆商品コード:BT2711-22
◆調査・発行会社:MarketsandMarkets
◆発行日:2022年4月11日
◆ページ数:182
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥0見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は、世界のヒトマイクロバイオーム市場規模が2023年269百万ドルから2029年1,370百万ドルまで、年平均31.1%成長すると予想しています。本市場調査資料では、ヒトマイクロバイオームの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、用途別(治療用、診断用)分析、技術別(ゲノミクス、プロテオミクス、メタボロミクス)分析、種類別(微生物叢コンソーシアム移植(FMT)、ペプチド、活性生物療法製品(LBP)、その他)分析、製品別(薬剤、診断検査、プロバイオティクス、プレバイオティクス、その他)分析、地域別分析、競争状況、企業情報などの項目を掲載しています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のヒトマイクロバイオーム市場規模:用途別(治療用、診断用)
・世界のヒトマイクロバイオーム市場規模:技術別(ゲノミクス、プロテオミクス、メタボロミクス)
・世界のヒトマイクロバイオーム市場規模:種類別(微生物叢コンソーシアム移植(FMT)、ペプチド、活性生物療法製品(LBP)、その他)
・世界のヒトマイクロバイオーム市場規模:製品別(薬剤、診断検査、プロバイオティクス、プレバイオティクス、その他)
・世界のヒトマイクロバイオーム市場規模:地域別
・競争状況
・企業情報

“The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029.” The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market’s growth.

“By product segment, the drugs segment accounted for the largest share of human microbiome market:”
Based on product, the human microbiome market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and other products. Drugs segment accounted for the largest product segment in the human microbiome market. The large share of this segment can be attributed to the increasing number of human microbiome-based drug products in clinical trials and rising funding to develop microbiome-based drugs

“By application, the diagnostics segment is expected to grow at the highest CAGR during the forecast period.”
Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR during the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.

“By genomic technologies, the sequencing segment is expected to grow at the highest CAGR during the forecast period.”
Based on technology, the human microbiome market is further segmented into sequencing and other genomic technologies {PCR, microarray, and fluorescent in situ hybridization (FISH)}. The availability of advanced, efficient, and accurate next-generation sequencing systems at a low cost, along with the reduced cost of sequencing, has greatly boosted the adoption of the latest sequencing technologies in the human microbiome market

“North America: The largest region in the human microbiome market.”
In the human microbiome market, North America is estimated to maintain its vanguard during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.

Breakdown of primaries:
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs.

The break-up of the primaries is as follows:
By Designation: Managers: 55%, Executives: 25%, and CXOs: 20%,
By Region: North America: 50%, Europe: 20%, APAC: 20%, and RoW: 10%

Prominent players in the human microbiome market include ENTEROME Bioscience (France), Seres Therapeutics. (US), 4D pharma (UK), OptiBiotix Health (UK), Synlogic (US), International flavors & Fragrances (US), Second Genome (US), Vedanta Biosciences (US), Ferring Pharmaceuticals (Switzerland), Evelo Biosciences (US), ViThera Pharmaceuticals (US), BiomX (Israel), Kaleido (US), YSOPIA Bioscience (France), FlightPath (US), Finch Therapeutics (US), Quantbiome (DBA Thyrve, Inc.) (US), Viome, Inc. (US), DayTwo (US), BIOHM (US), Atlas Biomed (UK), Bione (India), Luxia Scientific (France), Sun Genomics (US), and Metabiomics (US).

Research Coverage:
The report segments the human microbiome market based on region (Asia Pacific, Europe, North America, and RoW), product (prebiotics, probiotics, drugs, diagnostic tests, and other products), technology (Genomics, Proteomics, and Metabolomics), application (therapeutics and diagnostics), disease (hospitals & clinics, research centers and academic & government institutes, pharmaceutical & biotechnology companies, and other end users). The report also provides a comprehensive review of market drivers, opportunities, restraints, and challenges in the human microbiome market.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its subsegments. This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies. The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

【レポートの目次】

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.3 MARKET SCOPE 28
1.3.1 MARKETS COVERED 28
1.3.2 MARKETS COVERED FOR HUMAN MICROBIOME
RESEARCH SPENDING MARKET 29
1.3.3 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME
RESEARCH SPENDING MARKET) 29
1.3.4 YEARS COVERED FOR THE STUDY (HUMAN MICROBIOME MARKET) 30
1.4 CURRENCY 30
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH APPROACH 32
2.1.1 SECONDARY DATA 32
2.1.2 PRIMARY SOURCES 33
FIGURE 1 BREAKDOWN OF PRIMARIES: HUMAN MICROBIOME MARKET 33
2.2 MARKET DATA ESTIMATION AND TRIANGULATION 34
FIGURE 2 DATA TRIANGULATION METHODOLOGY 34
2.2.1 MARKET ESTIMATION METHODOLOGY 35
FIGURE 3 MARKET SIZE ESTIMATION APPROACH: R&D SPENDING ANALYSIS-BASED ESTIMATION (FOR HUMAN MICROBIOME RESEARCH SPENDING MARKET) 35
FIGURE 4 HUMAN MICROBIOME RESEARCH SPENDING MARKET SIZE
(USD MILLION): FINAL MARKET SIZE 35
2.2.2 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 36
FIGURE 5 FINAL CAGR PROJECTIONS (2023−2029) 36
2.2.3 POTENTIAL MARKET SIZE CALCULATION FOR HUMAN MICROBIOME MARKET 36
FIGURE 6 HUMAN MICROBIOME MARKET SIZE BASED ON EPIDEMIOLOGY APPROACH 37
2.3 INSIGHTS FROM PRIMARIES 37
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 37
2.4 RESEARCH ASSUMPTIONS 38

3 EXECUTIVE SUMMARY 39
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT,
2023 VS. 2029 (USD MILLION) 39
FIGURE 9 HUMAN MICROBIOME MARKET SHARE, BY APPLICATION, 2029 40
FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION) 40
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMAN MICROBIOME MARKET 41
4 PREMIUM INSIGHTS 42
4.1 HUMAN MICROBIOME: MARKET OVERVIEW 42
FIGURE 12 INCREASING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE MARKET GROWTH 42
4.2 HUMAN MICROBIOME MARKET, BY TYPE (2023 VS. 2029) 43
FIGURE 13 FMT TO DOMINATE HUMAN MICROBIOME MARKET IN 2023 43
4.3 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT & APPLICATION (2023) 43
4.4 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY COUNTRY (2023–2029) 44
FIGURE 14 CHINA TO GROW AT THE HIGHEST CAGR DURING FORECAST PERIOD 44
5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
5.2 MARKET DYNAMICS 46
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 46
5.2.1 MARKET DRIVERS 47
5.2.1.1 Rising industry-academia collaborations for microbiome research 47
5.2.1.2 Increasing focus on human microbiome therapeutics development 47
5.2.1.3 Human microbiome as a validated target for drug development 48
5.2.1.4 Development of human microbiome-based tests for early disease detection & diagnosis 48
5.2.2 MARKET RESTRAINTS 49
5.2.2.1 Barriers in proving the causal link between dysbiosis and diseases 49
5.2.2.2 Negative clinical data will adversely impact public perception of microbiomes 49
5.2.3 MARKET OPPORTUNITIES 49
5.2.3.1 Increasing collaborations between public-private organizations 49
5.2.4 MARKET CHALLENGES 51
5.2.4.1 Government regulations 51
5.2.4.2 Lack of expertise and inadequate research 51
5.3 IMPACT OF THE COVID-19 PANDEMIC ON THE HUMAN MICROBIOME MARKET 52
5.4 REGULATORY ANALYSIS 53
5.4.1 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED DRUGS 53
5.4.2 REGULATORY LANDSCAPE FOR HUMAN MICROBIOME-BASED FOODS 54
5.5 PATENT ANALYSIS 54

6 HUMAN MICROBIOME MARKET, BY APPLICATION 56
6.1 INTRODUCTION 57
TABLE 1 HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 57
6.2 THERAPEUTIC APPLICATIONS 57
6.2.1 AVAILABILITY OF FUNDING FOR MICROBIOME-BASED THERAPEUTIC PRODUCTS DEVELOPMENT TO DRIVE MARKET GROWTH 57
TABLE 2 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION,
2023–2029 (USD MILLION) 58
TABLE 3 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS,
BY COUNTRY 2023–2029 (USD MILLION) 58
TABLE 4 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY 2023–2029 (USD MILLION) 59
TABLE 5 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS,
BY COUNTRY 2023–2029 (USD MILLION) 59
6.3 DIAGNOSTIC APPLICATIONS 59
6.3.1 INCREASING FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET GROWTH 59
TABLE 6 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION,
2023–2029 (USD MILLION) 60
TABLE 7 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS,
BY COUNTRY 2023–2029 (USD MILLION) 60
TABLE 8 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY 2023–2029 (USD MILLION) 61
TABLE 9 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS,
BY COUNTRY 2023–2029 (USD MILLION) 61
7 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY 62
7.1 INTRODUCTION 63
TABLE 10 HUMAN MICROBIOME RESEARCH SPENDING MARKET, BY TECHNOLOGY, 2021–2029 (USD MILLION) 63
7.2 GENOMICS 63
TABLE 11 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS,
BY TYPE, 2021–2029 (USD MILLION) 63
TABLE 12 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS,
BY REGION, 2021–2029 (USD MILLION) 64
TABLE 13 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 64
TABLE 14 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 64
TABLE 15 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR GENOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 65
7.2.1 SEQUENCING 65
TABLE 16 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING,
BY REGION, 2021–2029 (USD MILLION) 65
TABLE 17 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION) 65
TABLE 18 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION) 66
TABLE 19 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING, BY COUNTRY, 2021–2029 (USD MILLION) 66
TABLE 20 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR SEQUENCING,
BY METHOD, 2021–2029 (USD MILLION) 66
7.2.1.1 16S rRNA Sequencing Method 67
7.2.1.1.1 Cost-effectiveness to propel identification of bacterial strains 67
TABLE 21 16S RRNA SEQUENCING METHOD, BY REGION, 2021–2029 (USD MILLION) 67
TABLE 22 NORTH AMERICA: 16S RRNA SEQUENCING METHOD, BY COUNTRY,
2018–2025 (USD MILLION) 67
TABLE 23 EUROPE: 16S RRNA SEQUENCING METHOD, BY COUNTRY,
2021–2029 (USD MILLION) 68
TABLE 24 ASIA PACIFIC: 16S RRNA SEQUENCING METHOD, BY COUNTRY,
2021–2029 (USD MILLION) 68
7.2.1.2 Whole-Genome Sequencing (WGS)Method 68
7.2.1.2.1 WGS to generate accurate reference genomes for microbial identification 68
TABLE 25 WGS METHOD, BY REGION, 2021–2029 (USD MILLION) 69
TABLE 26 NORTH AMERICA: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION) 69
TABLE 27 EUROPE: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION) 69
TABLE 28 ASIA PACIFIC: WGS METHOD, BY COUNTRY, 2021–2029 (USD MILLION) 69
7.2.1.3 Other Sequencing Methods 70
TABLE 29 OTHER SEQUENCING METHODS, BY REGION, 2021–2029 (USD MILLION) 70
TABLE 30 NORTH AMERICA: OTHER SEQUENCING METHODS, BY COUNTRY,
2021–2029 (USD MILLION) 70
TABLE 31 EUROPE: OTHER SEQUENCING METHODS, BY COUNTRY,
2021–2029 (USD MILLION) 70
TABLE 32 ASIA PACIFIC: OTHER SEQUENCING METHODS BY COUNTRY,
2021–2029 (USD MILLION) 71
7.2.2 OTHER GENOMIC TECHNOLOGIES 71
TABLE 33 HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY REGION, 2021–2029 (USD MILLION) 71
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION) 72
TABLE 35 EUROPE: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION) 72
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME RESEARCH SPENDING MARKET FOR OTHER GENOMIC TECHNOLOGIES, BY COUNTRY, 2021–2029 (USD MILLION) 72
7.3 PROTEOMICS 73
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMIC TECHNOLOGIES TO DRIVE MARKET GROWTH 73
TABLE 37 PROTEOMICS, BY REGION, 2021–2029 (USD MILLION) 73
TABLE 38 NORTH AMERICA: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 73
TABLE 39 EUROPE: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 74
TABLE 40 ASIA PACIFIC: PROTEOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 74
7.4 METABOLOMICS 74
7.4.1 ADVANTAGES OF METABOLOMICS OVER GENOMICS AND PROTEOMICS TO DRIVE MARKET GROWTH 74
TABLE 41 METABOLOMICS, BY REGION, 2021–2029 (USD MILLION) 75
TABLE 42 NORTH AMERICA: METABOLOMICS, BY COUNTRY,
2021–2029 (USD MILLION) 75
TABLE 43 EUROPE: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 75
TABLE 44 ASIA PACIFIC: METABOLOMICS, BY COUNTRY, 2021–2029 (USD MILLION) 75
8 HUMAN MICROBIOME MARKET, BY TYPE 76
8.1 INTRODUCTION 77
TABLE 45 HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 77
8.2 MICROBIOME CONSORTIA TRANSPLANTATION (FMT) 77
8.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR C. DIFFICILE INFECTION TREATMENT TO AUGMENT SEGMENTAL GROWTH 77
TABLE 46 HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY REGION, 2023–2029 (USD MILLION) 78
TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY
2023–2029 (USD MILLION) 78
TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION) 78
TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR MICROBIOME CONSORTIA TRANSPLANTATION (FMT), BY COUNTRY 2023–2029 (USD MILLION) 79
8.3 PEPTIDE 79
8.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO GROW IN FORECAST PERIOD 79
TABLE 50 HUMAN MICROBIOME MARKET FOR PEPTIDE, BY REGION,
2023–2029 (USD MILLION) 80
TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION) 80
TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY
2023–2029 (USD MILLION) 80
TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDE, BY COUNTRY 2023–2029 (USD MILLION) 81
8.4 LIVE BIOTHERAPEUTIC PRODUCT 81
8.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC
PRODUCTS TO BOOST SEGMENTAL GROWTH 81
TABLE 54 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT,
BY REGION, 2023–2029 (USD MILLION) 81
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION) 82
TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION) 82
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCT, BY COUNTRY 2023–2029 (USD MILLION) 82

8.5 OTHERS 83
8.5.1 INCREASING FOCUS ON SMALL MOLECULES TO PROPEL
SEGMENTAL GROWTH 83
TABLE 58 HUMAN MICROBIOME MARKET FOR OTHERS, BY REGION,
2023–2029 (USD MILLION) 83
TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION) 83
TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY
2023–2029 (USD MILLION) 84
TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHERS, BY COUNTRY 2023–2029 (USD MILLION) 84
9 HUMAN MICROBIOME MARKET, BY PRODUCT 85
9.1 INTRODUCTION 86
TABLE 62 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 86
9.2 DRUGS 86
9.2.1 INCREASING NUMBER OF MICROBIOME-BASED DRUGS
IN PIPELINE TO DRIVE SEGMENT GROWTH 86
TABLE 63 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION,
2023–2029 (USD MILLION) 87
TABLE 64 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 87
TABLE 65 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY,
2023–2029 (USD MILLION) 87
TABLE 66 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 88
9.3 DIAGNOSTIC TESTS 88
9.3.1 GROWING CONSUMER AWARENESS ABOUT MICROBIOME- BASED TESTS TO DRIVE SEGMENT GROWTH 88
TABLE 67 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION,
2023–2029 (USD MILLION) 89
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 89
TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS,
BY COUNTRY, 2023–2029 (USD MILLION) 90
TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS,
BY COUNTRY, 2023–2029 (USD MILLION) 90
9.4 PROBIOTICS 90
9.4.1 ONGOING RESEARCH PROMOTING CREDIBILITY REGARDING HEALTH CLAIMS AND SAFETY OF PROBIOTICS 90
TABLE 71 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION,
2023–2029 (USD MILLION) 91
TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023–2029 (USD MILLION) 91
TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 91
TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS,
BY COUNTRY, 2023–2029 (USD MILLION) 92
9.5 PREBIOTICS 92
9.5.1 DEVELOPMENT OF TARGETED PREBIOTICS IN ENHANCING GUT MICROBIOTA TO DRIVE SEGMENT GROWTH 92
TABLE 75 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION,
2023–2029 (USD MILLION) 93
TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023–2029 (USD MILLION) 93
TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 93
TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS,
BY COUNTRY, 2023–2029 (USD MILLION) 94
9.6 OTHER PRODUCTS 94
TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION,
2023–2029 (USD MILLION) 94
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2029 (USD MILLION) 95
TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2029 (USD MILLION) 95
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS,
BY COUNTRY, 2023–2029 (USD MILLION) 95
10 HUMAN MICROBIOME MARKET, BY DISEASE 96
10.1 INTRODUCTION 97
TABLE 83 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 97
10.2 INFECTIOUS DISEASES 97
10.2.1 INCREASING NUMBER OF CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO DRIVE SEGMENT GROWTH 97
TABLE 84 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES 98
TABLE 85 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION) 98
TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 98
TABLE 87 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2029 (USD MILLION) 99
TABLE 88 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 99
10.3 GASTROINTESTINAL DISEASES 99
10.3.1 INCREASING NUMBER OF CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO DRIVE SEGMENT GROWTH 99
TABLE 89 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES,
BY REGION, 2023–2029 (USD MILLION) 100
TABLE 90 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 91 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 92 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 101
10.4 ENDOCRINE & METABOLIC DISORDERS 101
10.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO DRIVE SEGMENT GROWTH 101
TABLE 93 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS
FOR METABOLIC DISEASES 102
TABLE 94 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION) 102
TABLE 95 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 102
TABLE 96 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 103
TABLE 97 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 103
10.5 CANCER 103
10.5.1 MICROBIOME-BASED PRODUCTS HAVE DEMONSTRATED EFFICACY
IN TREATMENT OF PELVIC AND COLON CANCER 103
TABLE 98 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION,
2023–2029 (USD MILLION) 104
TABLE 99 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER,
BY COUNTRY, 2023–2029 (USD MILLION) 104
TABLE 100 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY,
2023–2029 (USD MILLION) 104
TABLE 101 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 105
10.6 OTHER DISEASES 105
TABLE 102 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION,
2023–2029 (USD MILLION) 105
TABLE 103 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2029 (USD MILLION) 106
TABLE 104 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2029 (USD MILLION) 106
TABLE 105 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES,
BY COUNTRY, 2023–2029 (USD MILLION) 106
11 HUMAN MICROBIOME MARKET, BY REGION 107
11.1 INTRODUCTION 108
TABLE 106 HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION) 108
11.2 NORTH AMERICA 109
FIGURE 16 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 109
TABLE 107 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 110
TABLE 108 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 110
TABLE 109 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 110
TABLE 110 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2029 (USD MILLION) 111
11.2.1 US 111
11.2.1.1 Increasing investments by NIH in support of microbiome research to drive market growth 111
TABLE 111 US: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 112
TABLE 112 US: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 112
TABLE 113 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION) 112
11.2.2 CANADA 113
11.2.2.1 Increasing government support and funds to support market growth 113
TABLE 114 INDICATIVE LIST OF PROJECTS ON HUMAN MICROBIOME IN 2018 113
TABLE 115 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 114
TABLE 116 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 114
TABLE 117 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 114
11.3 EUROPE 115
FIGURE 17 EUROPE: HUMAN MICROBIOME MARKET SNAPSHOT 115
TABLE 118 EU MICROBIOME PROJECT 116
TABLE 119 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 116
TABLE 120 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 116
TABLE 121 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 117
TABLE 122 EUROPE: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2029 (USD MILLION) 117
11.3.1 GERMANY 117
11.3.1.1 Extended applications of microbiome research to therapeutic areas to boost adoption of microbiome-based products 117
TABLE 123 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 118
TABLE 124 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 118
TABLE 125 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 118
11.3.2 UK 119
11.3.2.1 Increasing focus on microbiome-based products development to drive market growth 119
TABLE 126 UK: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 119
TABLE 127 UK: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 119
TABLE 128 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023-2029 (USD MILLION) 120
11.3.3 FRANCE 120
11.3.3.1 Increasing funding to boost microbiome-based products development 120
TABLE 129 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 121
TABLE 130 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 121
TABLE 131 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 121
11.3.4 ROE 122
TABLE 132 ROE: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 122
TABLE 133 ROE: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 122
TABLE 134 ROE: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 122
11.4 ASIA PACIFIC 123
FIGURE 18 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 123
TABLE 135 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 124
TABLE 136 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 124
TABLE 137 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 124
TABLE 138 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY,
2023–2029 (USD MILLION) 125
11.4.1 CHINA 125
11.4.1.1 Large number of human microbiome research studies
to drive market growth 125
TABLE 139 INDICATIVE LIST OF HUMAN MICROBIOME RESEARCH STUDIES CONDUCTED IN CHINA 125
TABLE 140 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 126
TABLE 141 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 126
TABLE 142 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 127
11.4.2 JAPAN 127
11.4.2.1 Increasing focus on funding for microbiome-based products to drive market growth 127
TABLE 143 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 127
TABLE 144 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 128
TABLE 145 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 128
11.4.3 INDIA 128
11.4.3.1 Government funding to drive microbiome-based products development 128
TABLE 146 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 129
TABLE 147 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 129
TABLE 148 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 129
11.4.4 REST OF ASIA PACIFIC 130
TABLE 149 ROAPAC: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 130
TABLE 150 ROAPAC: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 131
TABLE 151 ROAPAC: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 131
11.5 REST OF THE WORLD (ROW) 131
TABLE 152 ROW: HUMAN MICROBIOME MARKET, BY PRODUCT,
2023–2029 (USD MILLION) 132
TABLE 153 ROW: HUMAN MICROBIOME MARKET, BY APPLICATION,
2023–2029 (USD MILLION) 132
TABLE 154 ROW: HUMAN MICROBIOME MARKET, BY DISEASE,
2023-2029 (USD MILLION) 132
12 COMPETITIVE LANDSCAPE 133
12.1 OVERVIEW 133
12.2 PRODUCT TYPE FOOTPRINT OF COMPANIES 133
TABLE 155 PRODUCT TYPE PORTFOLIO ANALYSIS:
HUMAN MICROBIOME MARKET (2021) 133
12.3 CLINICAL PHASE FOOTPRINT OF COMPANIES 134
TABLE 156 CLINICAL PHASE FOOTPRINT OF COMPANIES:
HUMAN MICROBIOME MARKET (2021) 134
12.4 DISEASE FOOTPRINT OF COMPANIES 134
TABLE 157 DISEASE FOOTPRINT OF COMPANIES: HUMAN MICROBIOME MARKET (2021) 134
12.5 COMPETITIVE SCENARIO 135
TABLE 158 HUMAN MICROBIOME MARKET: KEY DEALS, JANUARY 2020–JANUARY 2021 135
13 COMPANY PROFILES 137
13.1 MAJOR PLAYERS 137
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1.1 ENTEROME 137
TABLE 159 ENTEROME: BUSINESS OVERVIEW 137
13.1.2 SERES THERAPEUTICS 140
TABLE 160 SERES THERAPEUTICS: BUSINESS OVERVIEW 140
FIGURE 19 SERES THERAPEUTICS: COMPANY SNAPSHOT (2021) 140
13.1.3 4D PHARMA PLC 143
TABLE 161 4D PHARMA PLC: BUSINESS OVERVIEW 143
FIGURE 20 4D PHARMA PLC: COMPANY SNAPSHOT (2020) 143
13.1.4 INTERNATIONAL FLAVORS & FRAGRANCES INC. 146
TABLE 162 INTERNATIONAL FLAVORS & FRAGRANCES INC.: BUSINESS OVERVIEW 146
FIGURE 21 INTERNATIONAL FLAVORS & FRAGRANCES INC.:
COMPANY SNAPSHOT (2021) 147
13.1.5 OPTIBIOTIX HEALTH PLC. 149
TABLE 163 OPTIBIOTIX HEALTH PLC.: BUSINESS OVERVIEW 149
FIGURE 22 OPTIBIOTIX HEALTH PLC.: COMPANY SNAPSHOT (2020) 150
TABLE 164 PRODUCT LAUNCHES 152
13.1.6 SYNLOGIC, INC. 153
TABLE 165 SYNLOGIC: BUSINESS OVERVIEW 153
FIGURE 23 SYNLOGIC, INC.: COMPANY SNAPSHOT (2020) 153
13.1.7 SECOND GENOME INC. 155
TABLE 166 SECOND GENOME INC.: BUSINESS OVERVIEW 155
13.1.8 VEDANTA BIOSCIENCES, INC. 157
TABLE 167 VEDANTA BIOSCIENCES, INC.: BUSINESS OVERVIEW 157
13.1.9 FERRING PHARMACEUTICALS 159
TABLE 168 FERRING PHARMACEUTICALS: BUSINESS OVERVIEW 159
13.1.10 EVELO BIOSCIENCES, INC. 161
TABLE 169 EVELO BIOSCIENCES: BUSINESS OVERVIEW 161
FIGURE 24 EVEL0 BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020) 161
13.1.11 BIOMX 163
TABLE 170 BIOMX: BUSINESS OVERVIEW 163
FIGURE 25 BIOMX: COMPANY SNAPSHOT (2020) 163
13.1.12 YSOPIA BIOSCIENCE 166
TABLE 171 YSOPIA BIOSCIENCE: BUSINESS OVERVIEW 166
13.1.13 KALEIDO BIOSCIENCES, INC. 168
TABLE 172 KALEIDO BIOSCIENCES, INC.: BUSINESS OVERVIEW 168
FIGURE 26 KALEIDO BIOSCIENCES, INC.: COMPANY SNAPSHOT (2020) 168
13.1.14 FLIGHTPATH BIOSCIENCES, INC. 171
TABLE 173 FLIGHTPATH BIOSCIENCES, INC.: BUSINESS OVERVIEW 171
13.1.15 FINCH THERAPEUTICS GROUP, INC. 172
TABLE 174 FINCH THERAPEUTICS GROUP, INC.: BUSINESS OVERVIEW 172
FIGURE 27 FINCH THERAPEUTICS GROUP, INC.: COMPANY SNAPSHOT (2020) 172
13.1.16 QUANTBIOME, INC. (DBA OMBRE) 174
TABLE 175 QUANTBIOME, INC.: BUSINESS OVERVIEW 174
13.1.17 VIOME LIFE SCIENCES, INC. 175
TABLE 176 VIOME LIFE SCIENCES, INC.: BUSINESS OVERVIEW 175
13.1.18 BIOHM HEALTH 176
TABLE 177 BIOHM HEALTH: BUSINESS OVERVIEW 176
13.2 OTHER COMPANIES 178
13.2.1 DAYTWO 178
TABLE 178 DAYTWO: COMPANY OVERVIEW 178
13.2.2 ATLAS BIOMED 179
TABLE 179 ATLAS BIOMED: COMPANY OVERVIEW 179
13.2.3 BIONE 179
TABLE 180 BIONE: COMPANY OVERVIEW 179
13.2.4 LUXIA SCIENTIFIC 180
TABLE 181 LUXIA SCIENTIFIC: COMPANY OVERVIEW 180
13.2.5 METABIOMICS 180
TABLE 182 METABIOMICS: COMPANY OVERVIEW 180
13.2.6 SUN GENOMICS 181
TABLE 183 SUN GENOMICS: COMPANY OVERVIEW 181
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 182
14.1 DISCUSSION GUIDE 182
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 185
14.3 AVAILABLE CUSTOMIZATIONS 187
14.4 RELATED REPORTS 187
14.5 AUTHOR DETAILS 188



★調査レポート[ヒトマイクロバイオームの世界市場予測(~2029):製品別、用途別、疾患別、研究技術別] ( Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2029 / BT2711-22) 販売に関する免責事項
[ヒトマイクロバイオームの世界市場予測(~2029):製品別、用途別、疾患別、研究技術別] ( Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) - Global Forecast to 2029 / BT2711-22) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆